| ［1］ |
邓丹琪. 免疫抑制剂在皮肤科中的应用［J］. 皮肤病与性病, 2011,33（5）:262⁃264.
|
| ［2］ |
Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis［J］. Ther Clin Risk Manag, 2018,14:105⁃116. doi: 10.2147/TCRM.S154745.
|
| ［3］ |
Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children′s Arthritis and Rheumatology Research Alliance Consensus Conference［J］. Arthritis Care Res （Hoboken）, 2010,62（2）:219⁃225. doi: 10.1002/acr.20071.
|
| ［4］ |
Yadlapati S, Efthimiou P. Inadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?［J］. Rheumatol Int, 2016,36（5）:627⁃633. doi: 10.1007/s00296⁃016⁃3447⁃x.
|
| ［5］ |
Warren RB, Mrowietz U, von KR, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque⁃type psoriasis （METOP）: a 52 week,multicentre, randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2017,389（10068）:528⁃537. doi: 10.1016/S0140⁃6736（16）32127⁃4.
|
| ［6］ |
邱茜, 杨岫岩. 经典抗风湿药甲氨蝶呤的新观念［J］. 中华内科杂志, 2010,49（10）:820⁃821. doi: 10.3760/cma.j.issn.0578⁃1426.2010.10.002.
|
| ［7］ |
Lafforgue P, Monjanel⁃Mouterde S, Durand A, et al. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis［J］. J Rheumatol, 1995,22（5）:844⁃849.
|
| ［8］ |
Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis［J］. J Rheumatol, 2004,31（4）:645⁃648.
|
| ［9］ |
Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six⁃month, multicenter,randomized, double⁃blind, controlled, phase IV trial［J］. Arthritis Rheum, 2008,58（1）:73⁃81. doi: 10.1002/（ISSN）1529⁃0131.
|
| ［10］ |
Li D, Yang Z, Kang P, et al. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta⁃analysis［J］. Semin Arthritis Rheum, 2016,45（6）:656⁃662. doi: 10.1016/j.semarthrit.2015.11.004
|
| ［11］ |
Reich K, Langley RG, Papp KA, et al. A 52⁃week trial comparing briakinumab with methotrexate in patients with psoriasis［J］. N Engl J Med, 2011,365（17）:1586⁃1596. doi: 10.1056/NEJMoa 1010858.
|
| ［12］ |
Morgado⁃Carrasco D, Fustà⁃Novell X, Riera MJ, et al. The METOP study: further evidence for the use of subcutaneous methotrexate in psoriasis［J］. Actas Dermosifiliogr, 2017,108（9）:865⁃866. doi: 10.1016/j.ad.2017.04.007.
|
| ［13］ |
Yesudian PD, Leman J, Balasubramaniam P, et al. Effectiveness of subcutaneous methotrexate in chronic plaque psoriasis［J］. J Drugs Dermatol, 2016,15（3）:345⁃349.
|
| ［14］ |
Vidal D, Salleras M, Romani J, et al. Adherence of self⁃administered subcutaneous methotrexate in patients with chronic plaque⁃type psoriasis［J］. J Eur Acad Dermatol Venereol, 2016,30（11）:e131⁃e132. doi: 10.1111/jdv.13409
|
| ［15］ |
Bharadwaj A, Agrawal S, Batley M, et al. Use of parenteral methotrexate significantly reduces the need for biological therapy［J］. Rheumatology （Oxford）, 2008,47（2）:222. doi: 10.1093/rheumatology/kem306.
|
| ［16］ |
Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study［J］. Scand J Rheumatol, 2014,43（6）:470⁃476. doi: 10.3109/03009742.2014. 910312.
|
| ［17］ |
Fitzpatrick R, Scott DG, Keary I. Cost⁃minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate［J］. Clin Rheumatol, 2013,32（11）:1605⁃1612. doi: 10.1007/s10067⁃013⁃2318⁃z
|
| ［18］ |
Koduri GM, Mukhtyar C. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis［J］. Rheumatology （Oxford）, 2019,58（4）:559⁃560. doi: 10.1093/rheumatology/key097.
|
| ［19］ |
In brief: otrexup⁃⁃a single⁃use auto⁃injector formulation of methotrexate［J］. Med Lett Drugs Ther, 2014,56（1439）:28.
|
| ［20］ |
Schiff MH, Jaffe JS, Freundlich B. Head⁃to⁃head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug⁃exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration［J］. Ann Rheum Dis, 2014,73（8）:1549⁃1551. doi: 10.1136/annrheumdis⁃2014⁃205228.
|
| ［21］ |
Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high⁃concentration formulation［J］. Ther Adv Musculoskelet Dis, 2011,4（1）:3⁃9. doi: 10.1177/1759720X11431004.
|
| ［22］ |
Saraux A, Hudry C, Zinovieva E, et al. Use of auto⁃injector for methotrexate subcutaneous self⁃injections: high satisfaction level and good compliance in SELF⁃I study, a randomized, open⁃label, parallel group study［J］. Rheumatol Ther, 2019,6（1）:47⁃60. doi: 10.1007/s40744⁃018⁃0134⁃2
|
| ［23］ |
Owczarczyk⁃Saczonek A, Drozdowski M, Maciejewska⁃Radomska A, et al. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients ⁃ preliminary report［J］. Postepy Dermatol Alergol, 2018,35（1）:53⁃59. doi: 10.5114/ada.2017.71358
|
| ［24］ |
Reich K, Reich JLK, Falk TM, et al. Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1and 17 inflammatory pathways［J/OL］. Br J Dermatol, 2019. ［2019⁃07⁃05］. https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.18001. doi: 10.1111/bjd.18001.
|
| ［25］ |
刘海波, 刘芳, 桑红. 在皮肤学科指南中应用证据质量分级和推荐强度评价系统的意义［J］. 中华皮肤科杂志, 2018,51（9）:639⁃641. doi: 10.3760/cma.j.issn.0412⁃4030.2018.09.001.
|
